tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP
4.160USD
+0.310+8.05%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
4.27MMarktkapitalisierung
3.70KGV TTM

60 Degrees Pharmaceuticals Inc

4.160
+0.310+8.05%

mehr Informationen über 60 Degrees Pharmaceuticals Inc Unternehmen

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

60 Degrees Pharmaceuticals Inc Informationen

BörsenkürzelSXTP
Name des Unternehmens60 Degrees Pharmaceuticals Inc
IPO-datumJul 12, 2023
CEODow (Geoffrey S)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse1025 Connecticut Avenue Nw
StadtWASHINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20036
Telefon12023275422
Websitehttps://60degreespharma.com/
BörsenkürzelSXTP
IPO-datumJul 12, 2023
CEODow (Geoffrey S)

Führungskräfte von 60 Degrees Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Wed, Jan 21
Aktualisiert: Wed, Jan 21
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Andere
94.43%
Aktionäre
Aktionäre
Anteil
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Andere
94.43%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
3.72%
Individual Investor
1.39%
Corporation
0.66%
Investment Advisor/Hedge Fund
0.24%
Hedge Fund
0.06%
Bank and Trust
0.03%
Andere
93.89%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
25
52.23K
4.06%
-28.54K
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Orca Capital GmbH
166.23K
3.93%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
45.42K
1.07%
+22.63K
+99.30%
Dec 15, 2025
Knight Therapeutics, Inc.
33.90K
0.8%
+14.67K
+76.26%
Sep 30, 2024
DRW Securities, LLC
25.21K
0.6%
+25.21K
--
Sep 30, 2025
Xu (Cheryl)
15.82K
0.37%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.45K
0.29%
-67.00
-0.54%
Sep 30, 2025
Miller (Tyrone)
5.27K
0.12%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
Tower Research Capital LLC
3.14K
0.07%
+542.00
+20.86%
Sep 30, 2025
UBS Switzerland AG
1.48K
0.03%
+1.48K
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
KeyAI